药明巨诺 20260327 摘要 2025 年总收入 2.84 亿元（+79.3%），核心产品贝诺达销售 2.19 亿 元（+38.4%），毛利率升至 50.9%。 降本增效显著：单位成本由 78 万降至 50 万，研发与行政开支同比下降 超 33%，现金储备 5.03 亿元可支持 20 个月运营。 贝诺达二线大 B 细胞淋巴瘤适应症已于 2025H1 提交 NDA，并获突破 性疗法认定；慢病毒载体国产替代预计 2026 年获批。 全球创新资产 GWK239（四靶点 CAR-T）IIT 研究初步 ORR 达 100%，通过 Fas-CD2 等增强元件解决抗原逃逸与免疫抑制。 BD 进展活跃：非独家授权 BMS 慢病毒工艺获千万美元对价，与 Regeneron 合作 MAGE-A4 项目最高可获 5,000 万美元付款。 自免领域布局加速：Relma-cel 已递交系统性红斑狼疮 I 期数据，正寻 求合作伙伴以加速自免及实体瘤管线开发。 Q&A 2025 年药明巨诺的整体经营表现、业务进展及未来战略方向是怎样的？ 2025 年，公司在经营质量、核心业务推进及中长期战略规划方面取得了实质 性进展。财务表现上，全年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2126） 截至2025年12月31日止年度之年度業績公告 藥明巨諾（開曼）有限公司（「本公司」）之董事（「董事」）會（「董事會」）欣然公佈 本公司及其附屬公司（統稱「本集團」或「我們」）截至2025年12月31日止年度（「報 告期間」）之經審核簡明綜合業績，連同截至2024年12月31日止年度之比較數字。 年度業績摘要 財務摘要 國際財務報告準則計量： ‧ 收入於截至2025年12月31日止年度為人民幣283.7百萬元，較截至2024年12 月31日止年度的人民幣158.2百萬元增加79.3%。該收入主要來自(i)我們目 前處於商業化的產品倍諾達®的銷售；及(ii)向Juno授予JW sLVV生產工藝及 相關技術知識（以及專利）的非獨家許可。產品收入由截至2024 ...

Core Viewpoint - The pharmaceutical industry has recently experienced a significant pullback, particularly in the innovative drug sector, but there is a mild recovery in risk appetite due to government policies recognizing biomedicine as an emerging pillar industry [1] Industry Summary - The recent government work report has elevated the status of the pharmaceutical industry from a strategic emerging industry to an emerging pillar industry, indicating that policy benefits across the entire chain will continue to be released [1] - The combination of breakthroughs in AI drug development technology and the expansion of Chinese innovative drugs into overseas business development is expected to create a dual resonance, leading to an accelerated improvement in the industry's fundamentals [1] Company Recommendations - The company recommends buying shares in the following firms: - Innovent Biologics with a target price of HKD 110.62 - 3SBio with a target price of HKD 37.43 - JACOBY with a target price of HKD 10.34 - Genscript Biotech with a target price of HKD 44.95 - WuXi AppTec with a target price of HKD 88 [1]

藥明巨諾（開曼）有限公司*（「本公司」，連同其附屬公司，統稱「本集團」）董事（「董事」） 會（「董事會」）謹此宣佈，本公司謹訂於2026年3月26日（星期四）舉行董事會會議，藉 以（其中包括）(i)考慮及批准本集團截至2025年12月31日止年度之年度經審核綜合業績 及其發佈；(ii)建議之末期股息（如有）；以及(iii)處理任何其他事項。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告的全部或任何部份內容所產生 或因依賴該等內容而引致的任何損失承擔任何責任。 JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2126） 董事會會議通告 承董事會命 JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* 主席 劉誠 中國上海，2026年3月11日 於本公告日期，董事會包括主席兼非執行董事劉誠博士、執行董事田豐先生、非執行董事 Yiping James Li（李怡平）醫生、高星女士、Sungwon ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02126 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02126 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 USD | ...

Group 1 - The core viewpoint of the article is the announcement of the "2025 Sina Golden Unicorn Insurance Industry Awards" results, where WuXi AppTec was awarded the "Annual Excellence in Drug Insurance Ecosystem Integration and Innovation Award" [1][3]. Group 2 - The award highlights the recognition of innovation and integration within the drug insurance sector [1][3].

Core Viewpoint - The CAR-T therapy, despite being hailed as a "miracle drug" for cancer treatment, remains prohibitively expensive, with prices typically around one million yuan. However, a potential breakthrough is indicated by Huadao Biotech's submission for pre-market communication regarding its CAR-T drug, which may be priced between 230,000 to 250,000 yuan, significantly lowering the cost [1][2]. Group 1: Pricing and Market Dynamics - Huadao Biotech's CAR-T drug aims to reduce the price to 230,000-250,000 yuan, a drastic reduction from the current market prices [1]. - The market response to this potential price drop has been cautious, with stakeholders adopting a wait-and-see approach [1][2]. - In countries like India and Brazil, lower-priced CAR-T therapies have already been implemented, with India's NexCAR19 priced at approximately 200,000-300,000 yuan [1]. Group 2: Cost Reduction Strategies - Huadao Biotech plans to implement cost control measures similar to those used in India, focusing on local production of key raw materials and automation in manufacturing [2][4]. - The high cost of CAR-T therapies is attributed to their personalized nature and reliance on manual production processes, which are labor-intensive and costly [4]. - The localization of key raw materials, such as the slow virus vector, is a critical strategy for reducing production costs [4][6]. Group 3: Automation and Production Efficiency - The shift towards automated and closed production systems is seen as essential for enhancing efficiency and reducing costs in CAR-T manufacturing [7][8]. - Companies like Huadao Biotech are developing fully automated production facilities, which could significantly increase annual production capacity compared to existing products [8]. - The use of automated systems can reduce reliance on manual labor and minimize human error, potentially lowering production costs by up to 90% [8][9]. Group 4: Regulatory and Market Challenges - The success of Huadao Biotech's pricing strategy will depend on navigating stringent regulatory requirements and gaining market trust in the quality and efficacy of lower-priced therapies [2][10]. - The industry is closely monitoring the regulatory response to Huadao Biotech's application, as the approval of automated production methods remains limited [9][10]. - The competitive landscape is evolving, with emerging technologies like universal CAR-T and in vivo CAR-T showing promise for further cost reductions [10][11].

Core Insights - The article discusses the rapid growth and development of immunotherapy for cancer treatment, particularly focusing on immune cell therapies such as CAR-T, CAR-NK, TCR-T, and TIL therapies, which have become a significant fourth modality in cancer treatment alongside surgery, radiation, and drug therapy [1][4]. Industry Overview - Immunotherapy involves collecting young, healthy immune cells, expanding them in vitro, enhancing their targeting capabilities, and reinfusing them into patients to combat pathogens, cancer cells, and mutated cells [1][4]. - The global market for tumor immunotherapy products is projected to grow at a compound annual growth rate (CAGR) of 149.1% from 2017 to 2024, reaching a market size of $7.1 billion by 2025 [1][6]. - In China, the market for tumor immunotherapy products is expected to reach 2.1 billion yuan by 2025, driven by the approval of various immune cell therapy products [1][8]. Development Background - China has the highest incidence and mortality rates of cancer globally, with 4.8247 million new cases and 2.5742 million deaths reported in 2022, accounting for 24.1% and 26.5% of global totals, respectively [4]. - The increasing disposable income of Chinese residents has improved their ability to pay for medical care, with healthcare spending projected to reach 2,547 yuan per capita in 2024, growing by 3.6% [4][5]. Current Market Status - As of the end of 2024, there are 1,040 immunotherapy products in clinical trials, with the U.S. and China leading in the number of trials [10]. - CAR-T therapy is the most commercially mature and widely tested method, with 15 drugs approved globally by December 2025, 8 of which are approved in China [12]. Future Trends - The clinical transformation of immunotherapy is expected to accelerate, with market penetration likely to expand, potentially exceeding 10 billion yuan by 2027 [13]. - Advances in gene editing and AI-assisted target selection are anticipated to enhance treatment precision, while universal and multi-target cell products are expected to become mainstream in research [13][14].

药明巨诺-B(02126)发布公告，于2026年1月16日，公司根据2020年10月14日采纳的公司首次公开发售后 激励计划的条款将合共260万份购股权;及根据2020年10月14日采纳的公司首次公开发售后受限制股份单 位计划将合共65万个受限制股份单位授予公司四名承授人。 ...